Protagonist CEO sells 125K shares after option exercise
PTGX’s CEO exercised 125,000 options and sold the resulting shares over three days under a pre-arranged Rule 10b5-1 trading plan.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
4
Rhea-AI Filing Summary
Protagonist Therapeutics, Inc. (PTGX) reported that President and CEO Dinesh V. Patel exercised fully vested stock options for 125,000 shares of common stock at an exercise price of $21.58 per share on September 8, 9 and 10, 2026, and sold the same 125,000 shares in market or private transactions on those dates. The reported sale prices were weighted average prices of $145.87, $146.18 and $144.10 per share, respectively. All transactions were effected under a Rule 10b5-1 trading plan adopted on January 30, 2026.
Insider Trade Summary 10b5-1
Exercise and Sale: 125,000 shares ($15.54M approx. pre-tax spread)
Exercise and Sale
9 txns
Insider
PATEL DINESH V PH D
Role
President and CEO
Sold
125,000 shs ($18.24M)
Approx. gross sale proceeds
$18.24M
Approx. exercise cost
$2.70M
Approx. pre-tax spread
$15.54M
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Stock Option (right to buy) F1 | 7,278 | $0.00 | $0.00 |
| Exercise | Common Stock F1 | 7,278 | $21.58 | $157K |
| Sale | Common Stock F4 | 7,278 | $144.10 | $1.05M |
| Exercise | Stock Option (right to buy) F1 | 63,548 | $0.00 | $0.00 |
| Exercise | Common Stock F1 | 63,548 | $21.58 | $1.37M |
| Sale | Common Stock F3 | 63,548 | $146.18 | $9.29M |
| Exercise | Stock Option (right to buy) F1 | 54,174 | $0.00 | $0.00 |
| Exercise | Common Stock F1 | 54,174 | $21.58 | $1.17M |
| Sale | Common Stock F2 | 54,174 | $145.87 | $7.90M |
Holdings After Transaction:
Stock Option (right to buy) — 0 contracts (Direct);
Common Stock — 522,968 shares (Direct)
Footnotes (4)
- F1. The transactions set forth on this Form 4 were effected pursuant to a 10b5-1 plan adopted by the reporting person on January 30, 2026. The 10b5-1 plan provides for the exercise of fully vested stock options that expire on October 11, 2026, and the sale of shares of common stock acquired upon exercise of the stock options.
- F2. The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $142.00 to $147.29. Upon request by the staff of the U.S. Securities and Exchange Commission (the "SEC"), the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
- F3. The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $144.49 to $151.27. Upon request by the staff of the SEC, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
- F4. The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $142.51 to $145.19. Upon request by the staff of the SEC, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
Key Figures
Total shares exercised: 125,000 shares
Total shares sold: 125,000 shares
Option exercise price: $21.58 per share
+5 more
8 metrics
Total shares exercised
125,000 shares
Stock options exercised into common stock on September 8–10, 2026
Total shares sold
125,000 shares
Common shares sold in market or private transactions on September 8–10, 2026
Option exercise price
$21.58 per share
Exercise price of stock options converted into common stock
Weighted average sale price September 8, 2026
$145.87 per share
Shares sold in multiple transactions within a price range
Weighted average sale price September 9, 2026
$146.18 per share
Shares sold in multiple transactions within a price range
Weighted average sale price September 10, 2026
$144.10 per share
Shares sold in multiple transactions within a price range
Rule 10b5-1 plan adoption date
January 30, 2026
Date the pre-arranged trading plan governing these transactions was adopted
Option expiration date
October 11, 2026
Expiration date of the fully vested stock options exercised
Key Terms
Rule 10b5-1 plan, weighted average sale price per share, fully vested stock options, common stock
4 terms
Rule 10b5-1 plan regulatory
"The transactions set forth on this Form 4 were effected pursuant to a 10b5-1 plan adopted by the reporting person on January 30, 2026."
A Rule 10b5-1 plan is a prearranged, written schedule that lets corporate insiders buy or sell company stock at set times or amounts, even if they later learn material nonpublic information. Think of it like setting an automatic thermostat for trades: it creates a clear record that trades were planned in advance, reducing the risk of insider-trading accusations and helping investors trust that insider transactions are routine rather than based on secret information.
fully vested stock options financial
"The 10b5-1 plan provides for the exercise of fully vested stock options that expire on October 11, 2026, and the sale of shares of common stock acquired upon exercise of the stock options."
common stock financial
"and the sale of shares of common stock acquired upon exercise of the stock options."
Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transactions did PTGX’s CEO report in this Form 4?
President and CEO Dinesh V. Patel reported exercising stock options for 125,000 shares of Protagonist Therapeutics common stock and selling the same 125,000 shares in transactions dated September 8, 9 and 10, 2026.
What was the stock option exercise price in the PTGX CEO’s Form 4?
The stock options exercised by the PTGX CEO carried an exercise price of $21.58 per share. On each of September 8, 9 and 10, 2026, options were exercised at this price and converted into common shares that were then sold the same day.
Were the PTGX CEO’s transactions made under a Rule 10b5-1 plan?
Yes. A footnote states the transactions were effected pursuant to a Rule 10b5-1 plan adopted by the reporting person on January 30, 2026. The plan provides for exercising fully vested options expiring October 11, 2026 and selling the shares acquired upon exercise.
What type of securities did the PTGX CEO exercise in this filing?
The PTGX CEO exercised stock options that were fully vested and scheduled to expire on October 11, 2026. Each option entitled the holder to purchase one share of Protagonist Therapeutics common stock at an exercise price of $21.58 per share.
AI-generated analysis. How Rhea-AI works. Not financial advice.
